InteloMed, Inc. to Exhibit Non-Invasive Monitoring System for Assessing Dialysis Tolerance at the American Society of Nephrology Annual Kidney Week
The InteloMed CVInsight® Patient Monitoring & Informatics System will be featured at booth 1407.
PITTSBURGH, PA (November 15, 2016)– InteloMed, Inc., a leader in the development of advanced non-invasive systems for intelligent patient monitoring, will exhibit at the American Society of Nephrology (ASN) Kidney Week. InteloMed will feature the CVInsight® Patient Monitoring & Informatics System for continuous monitoring of cardiovascular stress to assess dialysis treatment tolerance. This year’s event is being held on November 17 – 20 in Chicago, IL. Kidney Week provides kidney professionals with opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field.
“InteloMed is proud to be part of the 50th year of ASN leading the fight against kidney diseases,” said InteloMed CEO Jill Schiaparelli. “We believe our CVInsight System is a forward step in the evolution of monitoring for dialysis patients and look forward to demonstrating its capabilities at Kidney Week.”
The CVInsight Monitoring System will be available at the InteloMed booth, number 1407. For more information about the event, visit http://www.asn-online.org/education/kidneyweek/.
InteloMed is redefining the standard of care in patient monitoring and informatics through its intelligent, multi-dimensional, non-invasive CVInsight® Patient Monitoring & Informatics System.
Providing an unprecedented level of physiologic insight, the CVInsight® Monitoring System is an easy-to-use, multi-parameter system for monitoring cardiovascular stress. It empowers clinicians with non-invasive, real-time, dynamic, and actionable information about a patient’s dialysis tolerance. Based on patented and proprietary algorithms, the system provides clinician set alerts to notify healthcare providers of changes in the patient’s tolerance to dialysis treatment, allowing them to intervene to avoid dialysis interruptions that can have serious patient consequences.
The CVInsight® Patient Monitoring and Informatics System is FDA-cleared and CE-marked and has launched commercially in the United States.
InteloMed is headquartered in Wexford, PA.
For more information, visit us at www.InteloMed.com.
The American Society of Nephrology (ASN) leads the fight against kidney diseases by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients. For more information, go to www.asn-online.org.
Safe Harbor Statement
Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.
Mike Dignazio, CFO
PR / Media Contact:
Matthew Bird, President